Your browser is no longer supported. Please, upgrade your browser.
Settings
AKRX Akorn, Inc. daily Stock Chart
AKRX [NASD]
Akorn, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own1.20% Shs Outstand119.79M Perf Week-4.01%
Market Cap430.05M Forward P/E18.60 EPS next Y0.19 Insider Trans1.77% Shs Float93.76M Perf Month-11.14%
Income-279.00M PEG- EPS next Q0.00 Inst Own73.70% Short Float8.60% Perf Quarter-49.65%
Sales726.70M P/S0.59 EPS this Y-128.00% Inst Trans-0.11% Short Ratio2.20 Perf Half Y-79.26%
Book/sh5.20 P/B0.69 EPS next Y359.52% ROA-13.90% Target Price8.00 Perf Year-89.14%
Cash/sh- P/C- EPS next 5Y15.00% ROE-33.40% 52W Range3.14 - 33.27 Perf YTD5.90%
Dividend- P/FCF165.40 EPS past 5Y-26.90% ROI-0.60% 52W High-89.21% Beta2.89
Dividend %- Quick Ratio2.50 Sales past 5Y26.80% Gross Margin41.80% 52W Low14.33% ATR0.30
Employees2284 Current Ratio3.50 Sales Q/Q-18.20% Oper. Margin-42.60% RSI (14)38.34 Volatility6.26% 8.63%
OptionableYes Debt/Eq1.26 EPS Q/Q- Profit Margin-34.70% Rel Volume0.77 Prev Close3.59
ShortableYes LT Debt/Eq1.26 EarningsFeb 05 BMO Payout- Avg Volume3.67M Price3.59
Recom2.70 SMA20-0.91% SMA50-30.35% SMA200-70.06% Volume2,818,210 Change0.00%
Oct-17-18Upgrade Piper Jaffray Neutral → Overweight
Jul-25-18Reiterated RBC Capital Mkts Sector Perform $25 → $27
Apr-25-17Downgrade Piper Jaffray Overweight → Neutral
Apr-25-17Downgrade Jefferies Buy → Hold
Apr-25-17Downgrade Gabelli & Co Buy → Hold
Mar-10-17Reiterated WallachBeth Hold $22 → $25
Dec-01-16Initiated Goldman Sell
Nov-07-16Downgrade WallachBeth Buy → Hold $40 → $22
Nov-07-16Downgrade BofA/Merrill Buy → Underperform
Nov-04-16Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $24
Sep-15-16Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated WallachBeth Buy $39 → $40
Aug-05-16Downgrade Deutsche Bank Buy → Hold $33 → $33
Aug-02-16Downgrade Raymond James Outperform → Mkt Perform
Mar-18-16Reiterated Deutsche Bank Buy $40 → $33
Feb-12-16Reiterated RBC Capital Mkts Outperform $52 → $37
Dec-02-15Upgrade Nomura Neutral → Buy
Sep-29-15Initiated Nomura Neutral
Sep-09-15Initiated JMP Securities Mkt Perform
Jul-21-15Initiated Susquehanna Neutral
Jan-10-19 02:54PM  Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility Zacks
Jan-09-19 07:07PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akorn, Inc. - AKRX PR Newswire -11.68%
06:40PM  Akorn, Inc. -- Moody's says receipt of FDA Warning Letter on Akorn's Decatur facility is credit negative Moody's
12:46PM  Akorn gets FDA warning letter for Illinois plant, shares drop Reuters
12:09PM  Akorn Slides After Reporting FDA Warning Letter On Illinois Facility Benzinga
08:04AM  Akorn gets warning letter from the FDA Reuters
08:01AM  Akorn receives 'warning letter' from FDA related to a manufacturing facility MarketWatch
07:55AM  Akorn Receives FDA Warning Letter GlobeNewswire
Jan-08-19 06:30PM  Akorn Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-21-18 02:00PM  Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX) Business Wire
12:57PM  Archer Capital Management Return, AUM, and Holdings Insider Monkey
07:58AM  The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial Benzinga
Dec-20-18 05:05PM  Akorn Names Douglas S. Boothe as President and CEO GlobeNewswire
Dec-14-18 04:25PM  Akorn, Inc. -- Moody's downgrades Akorn's ratings to Caa1; outlook revised to negative Moody's
Dec-10-18 03:18PM  Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX) Business Wire
01:24PM  After court case loss, drug maker Akorn's CEO will step down American City Business Journals
Dec-09-18 04:38AM  Is Akorn, Inc. (AKRX) A Good Stock To Buy? Insider Monkey
Dec-07-18 11:25PM  Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal Reuters -23.79%
08:27PM  Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Deal Bloomberg
05:04PM  Supreme Court of the State of Delaware Rules Against Akorn, New CEO Search Underway GlobeNewswire
01:08PM  Fresenius Wins Ruling on Canceled Buyout; Akorn Shares Fall Bloomberg
01:05AM  [$$] Akorn tumbles after US court upholds ruling on Fresenius deal cancellation Financial Times
Dec-06-18 12:35PM  Here's Why Akorn Pharmaceuticals Is Sinking Today Motley Fool -13.73%
Nov-26-18 05:29PM  Akorn Receives Product Approval GlobeNewswire
Nov-20-18 08:47AM  Do Options Traders Know Something About Akorn (AKRX) Stock We Don't? Zacks
Nov-19-18 09:35AM  Is Akorn (AKRX) Stock a Suitable Pick for Value Investors? Zacks
Nov-12-18 09:08AM  Investor Alert - Akorn, Inc. (AKRX) Kehoe Law Firm, P.C. Investigating Potential Claims Against Certain Officers and Directors of Akorn, Inc. GlobeNewswire
Nov-07-18 04:48PM  Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Akorn, Inc. (AKRX) and Encourages AKRX Investors to Contact the Firm GlobeNewswire -11.68%
05:08AM  Akorn: 3Q Earnings Snapshot Associated Press
Nov-06-18 05:10PM  Akorn Provides Third Quarter 2018 Results GlobeNewswire
Nov-05-18 11:35AM  Here's Why Akorn, Inc. Fell 48.6% in October Motley Fool
Oct-29-18 07:05AM  Akorn Receives Product Approval GlobeNewswire
Oct-23-18 05:56PM  Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600 PR Newswire
12:07AM  [$$] Saudi Arabias PIF under the crown prince was meant to drive domestic reform. Now its mired in a royal mess Financial Times
Oct-22-18 08:20AM  Akorn to Press Buyout Lawsuit Further, Extensive Product Line, Analysts Review and Target ACCESSWIRE -6.12%
Oct-19-18 11:00PM  [$$] Why the Delaware ruling on Akorn-Fresenius deal matters Financial Times
Oct-18-18 01:47PM  Akorn Appeals Fresenius Kabi Ruling GlobeNewswire
Oct-17-18 12:15PM  RM LAW Announces Investigation of Akorn, Inc. PR Newswire +6.26%
09:41AM  Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential Benzinga
12:08AM  [$$] Fresenius: kidney punch Financial Times
Oct-16-18 06:24PM  Akorn, Inc. -- Moody's downgrades Akorn to B3; outlook changed to developing Moody's +7.19%
08:42AM  Implied Volatility Surging for Akorn (AKRX) Stock Options Zacks
Oct-11-18 05:19PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders Business Wire
Oct-10-18 09:43AM  Akorn's Generic Drug For Inadequate Eye Lashes Receives FDA Nod Benzinga
07:22AM  Akorn's stock soars after FDA approves ANDA for hypotrichosis of eyelashes treatment MarketWatch
07:05AM  Akorn Receives Product Approval GlobeNewswire
Oct-01-18 04:49PM  Why Infinera, Akorn, and Cal-Maine Foods Slumped Today Motley Fool -58.71%
04:46PM  Akorn shares plummet after judge rules against Lake Forest drugmaker American City Business Journals
04:43PM  GE, Tesla and GM jump while Akorn plunges Associated Press
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg Video
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg
03:51PM  Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal Bloomberg
12:18PM  Trade pact lifts European shares while Italy extends slide Reuters
12:08PM  Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal Reuters
11:52AM  Here's Why Akorn Inc. Collapsed Today Motley Fool
09:42AM  Akorn stock set to drop nearly 50% after court supports Fresenius ending $4.3 bln merger MarketWatch
09:25AM  Akorn Comments on Delaware Chancery Court Ruling Business Wire
09:19AM  Judge says Fresenius can walk away from $4.8 bln Akorn deal Reuters
08:56AM  Judge rules for Fresenius in bid to end $4.8 bln Akorn deal Reuters
08:54AM  Fresenius shares jump on report of win in Akorn ruling Reuters
08:30AM  Akorn Plunges After Judge Backs Fresenius Exit From Deal Bloomberg
01:57AM  [$$] Court rules Fresenius can ditch $4.75bn Akorn deal Financial Times
Sep-13-18 09:35AM  Is Akorn (AKRX) a Suitable Stock for Value Investors Now? Zacks
09:30AM  AKRX vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Aug-28-18 06:50AM  Akorn Enters Oversold Territory Zacks
Aug-27-18 09:30AM  AKRX vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
08:48AM  Do Options Traders Know Something About Akorn (AKRX) Stock We Don't? Zacks
Aug-24-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Akorn ACCESSWIRE
Aug-23-18 04:33PM  Here's Why Akorn, Inc. Fell as Much as 24.1% Today Motley Fool -17.56%
Aug-01-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Jul-31-18 07:10AM  Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks ACCESSWIRE
Jul-30-18 08:00AM  Today's Research Reports on Trending Tickers: Aurora Cannabis and Akorn ACCESSWIRE
Jul-24-18 09:30AM  Oversold Biotechnology Companies ACCESSWIRE
Jul-13-18 08:39AM  Akorn (AKRX) Looks Good: Stock Adds 7.8% in Session Zacks -6.77%
08:00AM  Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals ACCESSWIRE
Jul-12-18 01:35PM  Fresenius Had Testing Woes Similar to Akorn, Unit Head Says Bloomberg +7.80%
01:35PM  Fresenius Had Testing Issues Similar to Akorn's, Executive Says Bloomberg
Jul-11-18 09:27PM  Execution blocked after company objects to use of its drug Associated Press
Jul-10-18 02:43PM  Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal Bloomberg
09:28AM  Lax Drugmaker Computer Security Linked to Deal Cancellation Bloomberg
Jul-09-18 10:30AM  Akorn Was Warned About Problems Before Merger, Executive Says Bloomberg
09:30AM  TEVA or AKRX: Which Is the Better Value Stock Right Now? Zacks
Jun-25-18 07:10AM  Free Technical Research on Akorn and Three More Generic Drugs Equities ACCESSWIRE
Jun-04-18 09:10AM  Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation GlobeNewswire
Jun-01-18 08:35AM  Options Traders Expect Huge Moves in Akorn (AKRX) Stock Zacks
May-29-18 03:31PM  Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc. PR Newswire
May-18-18 04:57AM  Fresenius CEO defends cancelled Akorn deal Reuters
May-11-18 07:00AM  Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks ACCESSWIRE
May-08-18 10:57AM  Top 3 Companies Owned by Valeant Investopedia
May-07-18 12:20PM  DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX ACCESSWIRE
11:05AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE
10:27AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 ACCESSWIRE
May-04-18 02:00PM  DEADLINE MONDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX) ACCESSWIRE
10:30AM  Pawar Law: Important May 7, 2018 Lead Plaintiff Deadline in Akorn, Inc. Class Action- AKRX ACCESSWIRE
10:07AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018 ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 12:30PM  MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm ACCESSWIRE -7.81%
12:13PM  AKRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018 ACCESSWIRE
09:58AM  Fresenius sees Akorn lawsuit dragging on into 2019 Reuters
May-02-18 11:48PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX Business Wire -14.97%
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BONACCORSI JOSEPHEVP Gen Counsel & SecretaryDec 14Buy4.4825,000112,000541,283Dec 18 05:00 PM
KAPOOR JOHN N10% OwnerJan 25Option Exercise26.4116,555437,188519,616Jan 26 06:00 PM
KAPOOR JOHN N10% OwnerJan 25Sale32.6713,629445,259505,987Jan 26 06:00 PM